4 articles
Science Corporation closes a $230 million Series C led by Khosla Ventures and Lightspeed, pushing its valuation past $1 billion as it targets European launch of the PRIMA vision-restoration implant by mid-2026.
Max Hodak's Science Corporation secured $230 million in Series C funding to commercialize PRIMA, a photovoltaic retinal implant restoring vision for geographic atrophy patients.
The neurotechnology company founded by Neuralink co-founder Max Hodak has raised $230 million at a $1.25 billion valuation, bringing its total funding to $489 million as it pushes toward commercialization of its retinal implant.
Max Hodak's Science Corporation secures $230 million to commercialize its retinal BCI implant, marking one of the largest funding rounds in neurotechnology as vision restoration approaches clinical reality.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. Unsubscribe anytime. We respect your privacy.